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Abstract
Background and purpose
Remote parenchymal haemorrhage (rPH) after intravenous thrombolysis is defined as hem-
orrhages that appear in brain regions without visible ischemic damage, remote from the
area of ischemia causing the initial stroke symptom. The pathophysiology of rPH is not clear
and may be explained by different underlying mechanisms. We hypothesized that rPH may
have different risk factors according to the bleeding location. We report the variables that we
found associated with deep and lobar rPH after intravenous thrombolysis.
Methods
This is a descriptive study of patients with ischemic stroke who were treated with intrave-
nous thrombolysis. These patients were included in a multicenter prospective registry. We
collected demographic, clinical and radiological data. We evaluated the number and distri-
bution of cerebral microbleeds (CMB) from Magnetic Resonance Imaging. We excluded
patients treated endovascularly, patients with parenchymal hemorrhage without concomi-
tant rPH and stroke mimics. We compared the variables from patients with deep or lobar
rPH with those with no intracranial hemorrhage.
Results
We studied 934 patients (mean age 73.9±12.6 years) and 52.8% were men. We observed
rPH in 34 patients (3.6%); 9 (0.9%) were deep and 25 (2.7%) lobar. No hemorrhage was
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observed in 900 (96.6%) patients. Deep rPH were associated with hypertensive episodes
within first 24 hours after intravenous thrombolysis (77.7% vs 23.3%, p<0.001). Lobar rPH
were associated with the presence of CMB (53.8% vs 7.9%, p<0.001), multiple (>1) CMB
(30.7% vs 4.4%, p = 0.003), lobar CMB (53.8% vs 3.0%, p<0.001) and severe leukoaraiosis
(76.9% vs 42%, p = 0.02).
Conclusions
A high blood pressure within the first 24 hours after intravenous thrombolysis is associated
with deep rPH, whereas lobar rPH are associated with imaging markers of amyloid deposi-
tion. Thus, our results suggest that deep and lobar rPH after intravenous thrombolysis may
have different mechanisms.
Introduction
The most serious complication of intravenous thrombolysis (IV-rtPA) in patients with acute
ischemic stroke is intracerebral hemorrhage (ICH), as these patients have a poor functional
outcome and high mortality [1].Thus, it is essential to identify risk factors that signal a future
ICH.
Remote parenchymal hemorrhage (rPH) is defined as single or multiple hemorrhages that
appear in brain regions without visible ischemic damage detected by cranial computed tomog-
raphy (CT), remote from the area of ischemic causing the initial symptom [2]. This type of
ICH occurs in 1.3–3.7% of patients within 24–36 hours after the infusion of IV-rtPA but risk
factors are not well-known [2–4]. It is likely that IV-rtPA triggers rPH when there is an under-
lying hemorrhagic-prone cerebral angiopathy, such as hypertensive and amyloid angiopathies
[2,4,5]. Similarly, spontaneous ICH occurs as the acute manifestation of a chronic cerebral vas-
culopathy and the most common accepted etiologies are cerebral amyloid angiopathy (CAA)
for lobar ICH and hypertension for deep ICH [6]. However, there are no reports of studies
that have investigated whether rPH after IV-rtPA risk factors are different depending on its
location.
Our aim was to evaluate clinical and radiological risk factors of deep and lobar rPH. We
hypothesized that deep rPH is associated with acute or chronic arterial hypertension, whereas
rPH in lobar regions is associated with Magnetic Resonance Imaging (MRI) markers of CAA.
Materials and methods
We report a retrospective, multicenter and descriptive study of patients with ischemic stroke
who were treated with IV-rtPA in Catalonia (Spain) between January 2011 and August 2013.
Since January 2011 all patient data were prospectively and consecutively included by stroke
neurologist in the SONIIA (Sistema Online d’Informacio´ de l’Ictus Agut) registry, a govern-
ment-mandated registry aiming at continuously monitoring the quality of all reperfusion ther-
apies administered for acute ischemic stroke in Catalonia.
Ethic statement
All of the authors collected the data used in this study. All data were included in the SONIIA
registry, a government-mandated, population-based, externally audited, prospective database
that includes all acute ischemic stroke patients treated with reperfusion therapies in the region
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of Catalonia from January 2011. Written or oral consent was taken from patients on admission
about any diagnostic and therapeutic procedure undertaken. The authors also obtained a writ-
ten or oral consent to use non-personal information included in the SONIIA registry for clini-
cal investigations. Since we applied a retrospective approach, all relevant information was
taken from the SONIIA registry, but without re-informing the patients. The SONIIA registry
satisfies all legal requirements mandated by the local law regarding protection of personal
data. A committee of stroke experts reviewed and ethically approved this study. They also
accepted the use of oral consent.
Study population
We included patients aged 18 years-old who had a stroke and underwent a follow-up cranial
tomography within the first 36 hours of IV-rtPA. ICH complications, including rPH, were
classified according to the European Cooperative Acute Stroke Study criteria [7]. Patients with
PH without concomitant rPH, stroke mimics and those who underwent endovascular treat-
ment were excluded. We analyzed the results of the MRI only if it was performed within the
first 14 days from onset of stroke.
We collected the following variables from 9 different Stroke Centers. Demographics: age
(years) and sex; medical history including prior arterial hypertension, diabetes, atrial fibrilla-
tion, transient ischemic attack or ischemic stroke; prior medication (use of antiplatelet agents
or anticoagulants); stroke severity assessed by the initial National Institutes of Health Stroke
Scale (NIHSS); laboratory data (platelet count and coagulation tests including activated partial
thromboplastin time and international normalized ratio); onset-to-needle time; hypertensive
episodes within the first 24 hours of IV-rtPA infusion defined as an increase more than once
of systolic blood pressure185 mmHg or diastolic blood pressure 105 mmHg within the
first 24 hours after IV-rtPA; hyperglycemia if capillary glucose levels were7.7 mmol/L within
the first 24 hours after IV-rtPA; type and location of the ICH according to the European Coop-
erative Acute Stroke Study criteria [7]. Hemorrhagic Infarction (HI) was defined as a petechial
infarction without space-occupying effect (HI1: small petechiae; HI2: more confluent pete-
chiae), parenchymal Hemorrhage (PH) was defined as a hemorrhage (coagulum) with mass
effect (PH1:<30% of the infarcted area with mild space-occupying effect; PH2:>30% of the
infarcted area with significant space-occupying effect), and rPH was defined as an extrais-
chemic remote hematoma, possibly multifocal in nature with and without mass effect (these
hemorrhages occurred on CT in brain regions without visible ischemic damage that was
remote from an ischemic infarct or in brains without visible ischemic lesion on CT). Lobar
rPH were defined as any extra ischemic ICH after IV-rtPA with selective involvement of the
cerebral cortex, underlying white matter, or both. Deep rPH were defined as any extra ische-
mic ICH after IV-rtPA with selective involvement of the basal ganglia, thalamus, internal cap-
sule, external capsule, corpus callosum, deep and periventricular white matter, brainstem or
cerebellum. We included patients with concomitant PH and rPH in the rPH group.
The MRI protocol was standardized at each hospital. All studies were performed within the
first 14 days from the onset of stroke and were evaluated by one reader (stroke neurologist or
neuroradiologist). In most patients, imaging was 1.5-T field strength and always included
T1-weighted, T2-weighted, fluid-attenuated inversion recovery (FLAIR), T2-weighted gradi-
ent-recalled echo sequences and diffusion weighted imaging. We evaluated the number and
location of cerebral microbleeds (CMB). CMB were defined as small (2-10mm), perivascular,
well demarcated hypointense, rounded lesions on MRI on T2-weighted gradient-recalled
echo sequences or sensitive to magnetic susceptibility [8]. The number of CMB was classified
as single (n = 1) or multiple (n>1). The location of CMB was classified as deep, lobar or
Risk factors for deep and lobar remote hemorrhage
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mixed. We classified as deep CMB when they were in the basal ganglia, thalamus, internal cap-
sule, external capsule, corpus callosum, deep and periventricular white matter or brainstem.
We classified as lobar CMB when they were in cortical and subcortical regions (including sub-
cortical U fibers). Mixed CMB were considered if the CMB were in deep and lobar locations
or CMB in cerebellum. Leukoaraiosis was assessed on FLAIR images with a simplified scale of
Fazekas and Schmidt [9]. We defined severe leukoaraiosis as a score of 2 (periventricular
smooth halo or deep beginning confluent foci) or 3 (periventricular irregular lesions extending
into deep white matter or deep confluent lesions). Cortical superficial siderosis was defined as
linear residues of blood products in the superficial layers of the cerebral cortex that showed a
characteristic gyriform pattern of low signal on T2 gradient-recalled echo images without cor-
responding hyperintense signal on T1-weighted or fluid-attenuated inversion recovery images
[10].
Statistical analysis
We compared all of the variables among patients with deep rPH and patients with no ICH,
and also among patients with lobar rPH and those with no ICH.
Due to the non-normal distribution of the continuous variables, the bivariate analyses were
performed with the Mann-Whitney U-test. Categorical variables were compared with Chi-
Square or the Fisher’s exact test. A p value <0.05 was considered statistically significant.
Results
Of the 1309 patients with stroke treated with IV-rtPA during the study period 378 were
excluded; thus 934 patients were included in the final analysis (Fig 1). Their mean age was 73.9
±12.6 years and 52.8% were men. We observed 25 (2.6%) patients with a lobar rPH, 9 (0.9%)
with a deep rPH and 900 with no ICH. We evaluated MRI results of 382 patients: 13 with lobar
rPH, 5 with deep rPH and 364 with no ICH.
Demographic variables, medical history, stroke severity, blood tests and onset-to-needle
time were not different between patients with deep rPH or lobar rPH and patients without any
ICH. (Table 1)
Hypertensive episodes within the first 24 hours of IV-rtPA were significantly more com-
mon in patients with deep rPH compared to patients with no ICH (77.7% vs 23.3%, p<0.001).
The presence of CMB (53.8% vs 7.9%, p<0.001), lobar distribution of CMB (53.8% vs 3.0%,
p<0.001), multiple CMB (30.7% vs 4.4%, p = 0.003) and severe leukoaraiosis (76.9% vs 42%,
p = 0.02) were significantly more frequent in patients with lobar rPH compared to those with-
out ICH. (Table 1).
Discussion
We found that deep rPH and lobar rPH exhibited different risk factors. Deep rPH was associ-
ated with hypertensive episodes within the first 24 hours after IV-rtPA infusion, whereas lobar
rPH was associated with neuroimaging surrogate markers of CAA.
There is increasing evidence of a link between CAA and ICH after IV-rtPA [2,11,12]. A
large meta-analysis [11] of patients with ischemic stroke who were treated with IV-rtPA
showed that patients who exhibited CMB and had a high burden of CMB were associated
with a high risk symptomatic ICH. A positron emission tomography study [12] found an asso-
ciation between patients with CAA and IV-rtPA associated ICH. However, in these studies
[11,12] a separate analysis of rPH was not reported. Recently, a multicenter study [2] showed
that lobar CMB were associated with rPH. In addition, rPH after IV-rtPA has been docu-
mented to occur at a site of CMB [13]. Leukoaraiosis or white matter hyperintensities include
Risk factors for deep and lobar remote hemorrhage
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a ubiquitous phenomenon of ageing, but occur with much greater volume in CAA patients
[14]. Progressive leukoaraiosis has been associated with incident lobar hemorrhages in CAA
patients [15]. In addition, a previous study showed that severe leukoaraiosis increased the risk
of rPH [4]. Finally, a pathological study of 5 patients with ICH after thrombolytic therapy in
myocardial infarction, showed that 3 of them had CAA [16]. All these findings, although
preliminary, suggest that a proportion of rPH is explained by the vascular fragility of CAA
together with the toxicity of IV-rtPA.
In patients without hypertension and a deep or infratentorial spontaneous ICH, blood pres-
sure160/100mmHg is sufficient evidence to conclude that bleedings are hypertension-
related [17]. Thus, in patients with an acute ischemic stroke, we feel safe in speculating that
deep rPH is the result of two concomitant processes (hypertensive episodes and IV-rtPA).
Similarly, patients with hypertension who are under treatment with anticoagulants have a high
risk of a spontaneous deep ICH [6]. Consistent with our findings, two large studies [3,18]
showed that a high systolic blood pressure after IV-rtPA is associated with rPH and any symp-
tomatic ICH. We do not know whether deep rPH can be prevented by a rapid and persistent
control of blood pressure in the acute phase of stroke, but this question may be answered by
the results of the on-going ENCHANTED trial [19].
Our results must be interpreted cautiously. First, this is a retrospective analysis from a pro-
spectively collected database. Like any register, reporting bias cannot be totally excluded,
although it was a mandatory and externally audited registry. Second, MRI results were evalu-
ated by different investigators according to local protocols, and without intra or inter-rater
variability analyses. Third, all of the MRI studies were performed after IV-rtPA. It is known
that 4.9–12.7% of acute stroke patients treated with IV-rtPA develop new CMB within the first
week after symptom onset, and thus, not all CMB demonstrated in the MRI may be chronic in
nature [20,21]. In addition, a pooled meta-analysis showed that patients with new CMB after
Fig 1. Study flow diagram (patients may had multiple reasons for not being included in the analysis).
MRI indicates magnetic resonance imaging.
https://doi.org/10.1371/journal.pone.0178284.g001
Risk factors for deep and lobar remote hemorrhage
PLOS ONE | https://doi.org/10.1371/journal.pone.0178284 June 22, 2017 5 / 9
IV-rtPA have an increased risk of rPH [22]. Fourth, we categorized hypertensive episodes
within the first 24 hours after IV-rtPA, but we did not know the number of hypertensive epi-
sodes of the exact time that blood pressure was uncontrolled. Fifth, our registry did not include
the total dose of IV-rtPA and the fibrinogen levels. It is documented that some patients with
ischemic stroke or myocardial infarction after a high dose of IV-rtPA have higher fibrinogen
degradation products and lower fibrinogen levels [16,23]. Fibrinogen degradation coagulopa-
thy after IV-rtPA is a relevant cause of symptomatic ICH and other major systemic bleeding
events [16,23]. Sixth, the low number of events was a limitation to find other etiologies of rPH
such as the use of anticoagulants, blood dyscrasias or structural vascular abnormalities [7,24].
A meta-analysis suggested an increased risk of symptomatic ICH after IV-rtPA in patients
with subtherapeutic (international normalized ratio1.7) warfarin therapy but a detailed anal-
ysis about rPH was not provided [24]. In our study there were 63 patients (2 deep rPH, 1 lobar
Table 1. Bivariate analyses of baseline variables of deep rPH, lobar rPH and patients without ICH.
Deep rPH
n = 9
Lobar rPH
n = 25
No ICH
n = 900
p value Deep rPH vs No
ICH
p value Lobar rPH vs No
ICH
Age, years, median (IQR) 78 (73–85) 78 (72–84) 77 (67–83) 0.46* 0.39*
Men, n (%) 3/9 (33.3) 13/25 (52) 477/900 (53) 0.32† 0.99†
Hypertension, n (%) 5/9 (55.5) 17/25 (68) 651/900 (72.3) 0.27† 0.65†
Diabetes, n (%) 3/9 (33.3) 4/25 (16) 213/900 (23.6) 0.45† 0.47†
Atrial fibrillation, n (%) 3/9 (33.3) 6/25 (24) 213/900 (23.6) 0.45† 0.99†
TIA/Stroke, n (%) 2/9 (22.2) 4/25 (16) 130/900 (14.4) 0.62† 0.77†
Antiplatelets, n (%) 4/9 (44.4) 13/25 (52) 330/900 (36.6) 0.73† 0.14†
Anticoagulants, n (%) 2/9 (22.2) 1/25 (4) 60/900 (6.6) 0.12‡ 0.99‡
Baseline NIHSS, median (IQR) 12 (6–15.5) 11 (5–19) 10 (6–17) 0.88* 0.66*
Onset-to-needle time (min), median
(IQR)
150 (125–
257)
144 (97–187) 135 (99–180) 0.08* 0.53*
Platelet count, 109/L, median (IQR) 210 (162–
236)
208 (180–243) 215 (177–257) 0.69* 0.43*
aPTT (ratio), median (IQR) 0.9 (0.8–0.9) 0.92 (0.85–
0.94)
0.89 (0.83–
0.94)
0.70* 0.44*
INR, median (IQR) 1.0 (1.0–1.2) 1.0 (0.9–1.1) 1.0 (0.9–1.1) 0.42* 0.92*
INR anticoagulants, median (IQR) 1.4 1.3 1.3 (1.2–1.5) 0.76* 0.95*
Hypertension 24h, n (%) 7/9 (77.7) 6/23 (26) 206/884 (23.3) <0.001† 0.60†
Hyperglycemia 24h, n (%) 2/9 (22.2) 3/23 (13) 180/789 (22.8) 0.99† 0.15†
1 CMB, n (%) 1/5 (20) 7/13 (53.8) 29/364 (7.9) 0.34‡ <0.001‡
>1 CMB, n (%) 0/5 (0) 4/13 (30.7) 16/359 (4.4) 0.99‡ 0.003‡
Lobar CMB, n (%) 1/5 (20) 7/13 (53.8) 11/364 (3.0) 0.15‡ <0.001‡
Deep CMB, n (%) 0/5 (0) 0/13 (0) 5/364 (1.3) 0.99‡ 0.99‡
Mixed CMB, n (%) 0/5 (0) 0/13 (0) 9/364 (2.4) 0.99‡ 0.99‡
Severe Leukoaraiosis, n (%) 0/5 (0) 10/13 (76.9) 153/360 (42) 0.07‡ 0.02‡
CSS, n (%) 1/5 (20) 1/13 (7.6) 4/354 (1.1) 0.06‡ 0.16‡
Values are expressed as absolute counts and percentage for categorical variables and median and interquartile range (IQR) for continuous variables. P
values are given for difference between patients with deep or lobar remote parenchymal hemorrhage (rPH) and patients without any intracranial
hemorrhage (ICH). The p values were obtained by Mann-Whitney U Test (*), χ2 Test (†) or Fisher exact test (‡). TIA, indicates transient ischemic attack;
NIHSS, National Institutes of Health Stroke Scale; aPTT, activated partial thromboplastin time; INR, international normalized ratio; INR anticoagulants,
international normalized ratio in patients who were treated with oral anticoagulants; Hypertension 24h, hypertensive episodes within first 24 hours of
intravenous thrombolysis; Hyperglycemia 24h, capillary glucose7.7 mmol/L within the first 24 hours of intravenous thrombolysis; CMB cerebral
microbleeds; Severe Leukoaraiosis, a score of 2 or 3 in a simplified scale of Fazekas and Schmidt [9]; CSS, cortical superficial siderosis.
https://doi.org/10.1371/journal.pone.0178284.t001
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and 60 without any ICH) who were treated with oral anticoagulants prior to IV-rtPA but the
international normalized ratio was not different between groups. Finally, we studied a small
number of patients with rPH. Thus, the results of the statistical analysis should be interpreted
cautiously, especially regarding the MRI substudy. In addition, due to the low number of
events, we could not perform multivariate analyses to adjust for confounding factors.
Although our findings are exploratory, they may facilitate the design of future studies to
clarify the risk factors of deep and lobar rPH. We believe that our results contribute to the
growing evidence of the association among patients with a high MRI burden of small-vessel
disease and rPH. However, our data do not justify withholding IV-rtPA in patients who are
otherwise candidates for this treatment or for primary endovascular reperfusion therapy.
Additionally, it seems prudent to prevent hypertensive episodes above the limits established by
current guidelines.
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